

Bandhan Bank reported a 6% PAT beat at Rs9.4bn and RoA of 2.1%, mainly led by higher other income and lower than expected provisions – better than some peers that posted sharp earning downgrades. The bank has logged a healthy AUM growth of 22% YoY/4% QoQ, supported by growth in its secured loan portfolio (~47% of loans). Deposits too grew swiftly, by 27% YoY/7% QoQ, leading to contraction in LDR by 282bps to 88%, which in turn led to a fall of 20bps in NIMs to 7.4%. Overall gross slippages remained elevated at Rs11bn/4.4% of loans, while absence of write-offs led to a 45bps QoQ uptick in GNPA to 4.7%. Management expects slippages to stay elevated in Q3, before cooling down in Q4. The bank shall soon apply for the ECLGS claim of Rs3.5bn, apart from balance CGFMU dues of Rs3.1bn. Further, ex-SBI DMD Partha Sengupta was appointed as the new MD & CEO wef 1-Nov-24 for three years, in line with the trend of PSB bankers joining troubled private banks. We retain REDUCE on Bandhan and TP of Rs175 (1x Sep-26E ABV) amid rising MFI stress.

Bandhan Bank: Financial Snapshot (Standalone)

Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Net profit	21,946	22,296	36,312	43,427	55,469
AUM growth (%)	9.8	14.3	17.0	19.0	22.0
NII growth (%)	6.3	11.5	17.8	17.3	18.8
NIM (%)	6.7	6.7	6.8	6.7	6.5
PPOP growth (%)	(11.5)	(6.4)	22.7	10.9	23.2
Adj. EPS (Rs)	13.6	13.8	22.5	27.0	34.4
Adj. EPS growth (%)	1,644.5	1.6	62.9	19.6	27.7
Adj. BV (INR)	115.9	127.9	147.5	169.2	198.3
Adj. BVPS growth (%)	15.1	10.4	15.3	14.7	17.2
RoA (%)	1.5	1.3	1.9	1.9	2.0
RoE (%)	11.9	10.8	15.5	16.0	17.7
P/E (x)	12.3	12.1	7.5	6.2	4.9
P/ABV (x)	1.4	1.3	1.1	1.0	0.8

Source: Company, Emkay Research

Secured loans foster healthy credit growth, but soften margins

Bandhan Bank has reported a healthy AUM growth of 22% YoY/4% QoQ (net credit growth of 24% YoY/4% QoQ), mainly due to higher growth in the corporate and housing segment. The MFI book declined 4% QoQ due to lower disbursements, as the management remained cautious amid rising asset quality concerns. The secured portfolio share has now reached ~47% as of Q2 which the management plans to take it up to ~50% by Mar-25. The bank's deposits also saw swift growth, of 27% YoY/7% QoQ, leading to contraction in LDR by 282bps to 88%, which in turn led to a fall in NIM by 20bps to 7.4%. The bank has guided to 18% credit growth in FY25 and for NIM to settle in the 7-7.5% range due to rising share of secured loans.

Rising industry-wide MFI stress remains a concern

Gross slippages remain elevated at Rs11bn/4.4% of loans due to persistent stress in the MFI book which, coupled with absence of write-offs, led to a 45bps QoQ uptick in GNPA to 4.7%; collection efficiency declined slightly, from 98.5% in Jun-24 to 97.8% in Sep-24. 60% of the bank's customers are unique customers and Bandhan+4 borrowers constitute ~4.5% of the total borrowers – relatively lower than that for a few peers. Management expects slippages to remain elevated in Q3 as well, before cooling down in Q4. Credit costs in Q2 were largely in line with guidance of 1.5-2% for FY25. Of the total assessed CGFMU claim of Rs12.3bn, the bank has already received Rs9.2bn and will shortly apply for claiming balance Rs3.1bn. It shall also submit fresh claims for Rs3.5bn wrt its ECLGS portfolio.


We retain REDUCE with TP of Rs175

We fine-tune our earnings for FY25-27E, and expect the bank to clock 1.9-2% RoA – well below its historical trajectory, given rising share of secured portfolio leading to structural margin contraction and continued asset-quality issues. We retain REDUCE on Bandhan Bank with unchanged TP of Rs175 (1x Sep-26E ABV). Further, ex-SBI DMD Partha Sengupta was appointed as the new MD & CEO wef 1-Nov-24 for three years, in line with the trend of PSB bankers joining troubled private banks. Key risks: Better than expected growth driven by secured loans, and lower than expected delinquencies/LLP.

Target Price – 12M	Sep-25
Change in TP (%)	-
Current Reco.	REDUCE
Previous Reco.	REDUCE
Upside/(Downside) (%)	4.0
CMP (25-Oct-24) (Rs)	168.2

Stock Data	Ticker
52-week High (Rs)	263
52-week Low (Rs)	167
Shares outstanding (mn)	1,611.0
Market-cap (Rs bn)	271
Market-cap (USD mn)	3,223
Net-debt, FY25E (Rs mn)	NA
ADTV-3M (mn shares)	21
ADTV-3M (Rs mn)	4,144.0
ADTV-3M (USD mn)	49.3
Free float (%)	47.0
Nifty-50	24,181
INR/USD	84.1
Shareholding, Sep-24	
Promoters (%)	40.0
FPIs/MFs (%)	26.7/16.3

Price Performance			
(%)	1M	3M	12M
Absolute	(17.8)	(9.5)	(22.9)
Rel. to Nifty	(11.6)	(8.6)	(39.1)



Anand Dama

anand.dama@emkayglobal.com
+91 22 6624 2480

Nikhil Vaishnav

nikhil.vaishnav@emkayglobal.com
+91 22 6624 2485

Kunaal N


kunaal.n@emkayglobal.com
+91 22 6612 1275

Marazbaan Dastur

marazbaan.dastur@emkayglobal.com
+91 22 6612 1281


Story in Charts

Exhibit 1: Bandhan Bank clocked a healthy AUM growth in 2Q, but MFI (EEB) growth remains lackluster...




Source: Company, Emkay Research

Exhibit 2: ...as also the deposit growth




Source: Company, Emkay Research

Exhibit 3: Portfolio diversification continues, with share of MFI on a declining course




Source: Company, Emkay Research

Exhibit 4: Lower loan yields led to margin contraction




Source: Company, Emkay Research

Exhibit 5: GNPA ratio inched-up slightly, owing to stress in the MFI space




Source: Company, Emkay Research

Exhibit 6: Collection efficiency declined QoQ, raising concerns on asset quality in MFI




Source: Company, Emkay Research

Exhibit 7: RoA on recovery course, but unlikely to get closer to the historical highs, given the changing business model and near-term asset quality challenges



Source: Company, Emkay Research

Exhibit 8: The stock currently trades at 1x 1Y forward ABV



Source: Bloomberg, Emkay Research

Exhibit 9: Actuals vs. Estimates (Q2FY25)

(Rs mn)	Actuals	Estimates		Variation		Comments
		Emkay	Consensus	Emkay	Consensus	
Net income	35,430	35,486	34,541	0%	3%	Healthy credit growth and other income lead to in-line Net income
PPOP	18,551	18,877	19,267	-2%	-4%	Higher staff/operating expenses result in a slight miss
PAT	9,374	8,884	8,902	6%	5%	Lower than expected provisions lead to PAT beat

Source: Company, Emkay Research

Exhibit 10: Quarterly Summary

(Rs mn)	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	YoY (%)	QoQ (%)	FY24	FY25E	YoY (%)
Interest Earned	44,919	46,654	51,893	55,358	55,358	22	-1	188,696	228,699	21
Interest Exp	20,486	21,401	23,231	25,308	25,308	25	1	85,440	107,059	25
Net Interest Income	24,434	25,254	28,663	30,050	30,050	21	-2	103,256	121,640	18
Global NIMs (reported)	7.20	7.20	7.60	7.60	7.60	20bps	-20bps	6.67	6.76	8bps
Non-interest Income	5,403	5,452	6,941	5,275	5,275	10	13	21,647	28,664	32
Operating Expenses	14,002	14,152	17,219	15,917	15,917	21	6	58,508	68,820	18
Pre Provisioning Profit	15,834	16,553	18,385	19,409	19,409	17	-4	66,395	81,484	23
Provision & Contingencies	6,362	6,840	17,743	5,230	5,230	-5	16	36,966	33,579	-9
PBT	9,472	9,713	642	14,179	14,179	32	-12	29,429	47,905	63
Income Tax Expense (Gain)	2,261	2,386	95	3,544	3,544	38	-12	7,133	11,593	63
Net Profit/(Loss)	7,212	7,327	546	10,635	10,635	30	-12	22,296	36,312	63
Gross NPA (%)	7.32	7.02	3.84	4.23	4.23	-264bps	45bps	3.84	4.60	76bps
Net NPA (%)	2.32	2.21	1.11	1.15	1.15	-103bps	14bps	1.11	1.33	22bps
Deposits (Rs bn)	1,121	1,174	1,352	1,332	1,332	27	7	1,352	1,671	24
Net Advances (Rs bn)	1,020	1,102	1,211	1,216	1,216	24	4	1,211	1,408	16

Source: Company, Emkay Research

Exhibit 11: Revision in estimates

Y/E Mar (Rs mn)	FY25E			FY26E			FY27E		
	Earlier	Revised	Change	Earlier	Revised	Change	Earlier	Revised	Change
Net income	150,829	150,304	-0.3%	171,671	169,541	-1.2%	203,370	201,086	-1.1%
PPOP	83,310	81,484	-2.2%	94,880	90,363	-4.8%	116,617	111,371	-4.5%
PAT	36,361	36,312	-0.1%	47,521	43,427	-8.6%	58,442	55,469	-5.1%
EPS (Rs)	22.6	22.5	-0.1%	29.5	27.0	-8.6%	36.3	34.4	-5.1%
BV (Rs)	156.3	156.2	0.0%	182.3	179.7	-1.4%	214.0	209.6	-2.1%

Source: Company, Emkay Research

Exhibit 12: Key assumptions

(%)	FY24	FY25E	FY26E	FY27E
Loan Growth	14.3	17.0	19.0	22.0
Deposit Growth	25.1	23.6	21.7	23.8
NIM	6.7	6.8	6.7	6.5
GNPA	3.8	4.6	4.5	4.0
Credit Cost	3.2	2.4	2.1	2.0

Source: Emkay Research

Exhibit 13: Key ratios and trends

	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25
Loans (Rs mn)	958,300	977,900	1,091,200	1,031,690	1,076,300	1,101,800	12,11,368	1,215,900	1,260,557
Growth YoY (%)	17.4	11.1	9.8	6.7	12.3	12.7	11.0	17.9	17.1
Loans QoQ (%)	(0.8)	2.0	11.6	(5.5)	4.3	2.4	9.9	0.4	3.7
Composition (%)									
Micro-Banking assets	56.3	54.0	52.1	49.7	50.2	50.0	49.9	49.1	45.3
Non -Micro banking assets	43.7	46.0	47.9	50.3	49.8	50.0	50.1	50.9	54.7
Liability Profile									
Deposits (Rs mn)	993,658	1,022,830	1,080,693	1,084,800	1,120,792	1,174,220	13,52,020	1,332,100	1,425,095
Growth YoY (%)	21.3	21.0	12.2	16.6	12.8	14.8	25.1	22.8	27.2
Growth QoQ (%)	6.8	2.9	5.7	0.4	3.3	4.8	15.1	(1.5)	7.0
CASA (%)	40.8	36.4	39.3	36.0	38.5	36.1	37.1	33.4	33.2
CA (%)	5.1	4.6	5.9	4.8	5.6	5.7	7.1	4.6	4.5
SA (%)	35.7	31.7	33.3	31.2	32.9	30.4	29.9	28.8	28.7
Asset Quality (Rs mn)									
Gross NPA	68,539	69,648	52,986	69,604	78,738	81,355	47,849	53,044	61,053
GNPA (%)	7.2	7.2	4.9	6.8	7.3	7.0	3.8	4.2	4.7
NPA	16,782	17,113	12,283	21,407	23,652	24,396	13,476	13,964	16,202
NNPA (%)	1.9	1.9	1.2	2.2	2.3	2.2	1.1	1.1	1.3
PCR – Specific (%)	75.5	75.4	76.8	69.2	70.0	70.0	71.8	73.7	73.5
Capital Adequacy									
CAR (%)	19.4	19.1	19.8	19.8	19.2	19.8	18.3	15.0	14.3
Tier I (%)	18.4	18.1	18.7	18.8	18.2	16.9	17.2	14.1	13.6
ROA (%)	0.6	0.8	2.2	1.9	1.9	1.9	0.1	2.5	2.1
ROE (%)	4.5	6.2	17.0	14.4	14.0	14.0	1.0	18.8	16.0

Source: Company, Emkay Research

Bandhan Bank: Standalone Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Interest Income	159,047	188,696	228,699	264,588	310,925
Interest Expense	66,451	85,440	107,059	121,852	141,315
Net interest income	92,596	103,256	121,640	142,735	169,610
NII growth (%)	6.3	11.5	17.8	17.3	18.8
Other income	24,686	21,647	28,664	26,806	31,476
Total Income	117,282	124,903	150,304	169,541	201,086
Operating expenses	46,368	58,508	68,820	79,178	89,715
PPOP	70,913	66,395	81,484	90,363	111,371
PPOP growth (%)	(11.5)	(6.4)	22.7	10.9	23.2
Core PPOP	70,173	65,040	79,977	88,705	109,548
Provisions & contingencies	41,984	36,966	33,579	33,070	38,192
PBT	28,930	29,429	47,905	57,292	73,179
Extraordinary items	0	0	0	0	0
Tax expense	6,983	7,134	11,593	13,865	17,709
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
Reported PAT	21,946	22,296	36,312	43,427	55,469
PAT growth (%)	1,644.6	1.6	62.9	19.6	27.7
Adjusted PAT	21,946	22,296	36,312	43,427	55,469
Diluted EPS (Rs)	13.6	13.8	22.5	27.0	34.4
Diluted EPS growth (%)	1,646.3	1.6	62.9	19.6	27.7
DPS (Rs)	1.5	1.5	2.5	3.5	4.5
Dividend payout (%)	11.0	10.8	11.1	13.0	13.1
Effective tax rate (%)	24.1	24.2	24.2	24.2	24.2
Net interest margins (%)	6.7	6.7	6.8	6.7	6.5
Cost-income ratio (%)	39.5	46.8	45.8	46.7	44.6
Shares outstanding (mn)	1,610.8	1,610.9	1,611.0	1,611.0	1,611.0

Source: Company, Emkay Research

Asset quality and other metrics					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Asset quality					
Gross NPLs	52,986.2	47,848.8	67,005.8	77,691.8	83,775.7
Net NPLs	12,282.7	13,476.1	18,761.6	22,530.6	24,295.0
GNPA ratio (%)	4.9	3.8	4.6	4.5	4.0
NNPA ratio (%)	1.2	1.1	1.3	1.3	1.2
Provision coverage (%)	76.8	71.8	72.0	71.0	71.0
Gross slippages	96,626.9	56,816.8	47,892.5	53,430.0	60,839.0
Gross slippage ratio (%)	7.7	3.8	3.2	3.0	2.8
LLP ratio (%)	4.0	3.1	2.4	2.1	2.0
NNPA to networth (%)	6.0	6.0	7.1	7.4	6.8
Capital adequacy					
Total CAR (%)	19.7	18.3	18.3	17.7	16.8
Tier-1 (%)	18.7	17.2	17.4	16.9	16.1
CET-1 (%)	18.7	17.2	17.4	16.9	16.1
RWA-to-Total Assets (%)	66.5	67.9	67.0	67.0	67.0
Miscellaneous					
Total income growth (%)	10.1	14.5	22.4	13.2	17.5
Opex growth (%)	31.6	26.2	17.6	15.1	13.3
Core PPOP growth (%)	(9.8)	(7.3)	23.0	10.9	23.5
PPOP margin (%)	38.6	31.6	31.7	31.0	32.5
PAT/PPOP (%)	30.9	33.6	44.6	48.1	49.8
LLP-to-Core PPOP (%)	59.8	56.8	42.0	37.3	34.9
Yield on advances (%)	14.1	14.8	15.7	15.4	15.0
Cost of funds (%)	5.3	6.0	6.4	6.1	5.9

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	16,108	16,109	16,110	16,110	16,110
Reserves & surplus	179,733	199,988	235,751	273,361	321,581
Net worth	195,841	216,097	251,861	289,471	337,691
Deposits	1,080,693	1,352,019	1,671,209	2,033,899	2,517,263
Borrowings	247,108	163,716	134,963	122,853	130,386
Interest bearing liab.	1,327,801	1,515,735	1,806,172	2,156,753	2,647,649
Other liabilities & prov.	34,057	46,585	33,416	33,903	58,150
Total liabilities & equity	1,557,700	1,778,416	2,091,448	2,480,126	3,043,490
Net advances	1,047,568	1,211,368	1,407,987	1,672,410	2,048,157
Investments	323,659	292,875	368,531	438,882	563,797
Cash, other balances	82,497	161,705	189,648	230,773	278,003
Interest earning assets	1,453,724	1,665,948	1,966,165	2,342,065	2,889,957
Fixed assets	8,546	11,735	13,108	14,644	16,362
Other assets	95,430	100,733	112,175	123,417	137,171
Total assets	1,557,700	1,778,416	2,091,448	2,480,126	3,043,490
BVPS (Rs)	121.6	134.1	156.2	179.7	209.6
Adj. BVPS (INR)	115.9	127.9	147.5	169.2	198.3
Gross advances	1,088,271	1,211,368	1,456,231	1,727,572	2,107,637
Credit to deposit (%)	96.9	89.6	84.2	82.2	81.4
CASA ratio (%)	39.3	37.1	33.3	32.6	33.6
Cost of deposits (%)	5.3	6.0	6.3	6.2	5.9
Loans-to-Assets (%)	67.3	68.1	67.3	67.4	67.3
Net advances growth (%)	11.5	15.6	16.2	18.8	22.5
Deposit growth (%)	12.2	25.1	23.6	21.7	23.8
Book value growth (%)	12.7	10.3	16.5	15.0	16.7

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY23	FY24	FY25E	FY26E	FY27E
P/E (x)	12.3	12.1	7.5	6.2	4.9
P/B (x)	1.5	1.3	1.1	0.9	0.8
P/ABV (x)	1.4	1.3	1.1	1.0	0.8
P/PPOP (x)	3.8	4.1	3.3	3.0	2.4
Dividend yield (%)	0.9	0.9	1.5	2.1	2.7
DuPont-RoE split (%)					
NII/avg assets	6.3	6.2	6.3	6.2	6.1
Other income	1.7	1.3	1.5	1.2	1.1
Fee income	1.6	1.2	1.1	1.1	1.1
Opex	3.1	3.5	3.6	3.5	3.2
PPOP	4.8	4.0	4.2	4.0	4.0
Core PPOP	4.8	3.9	4.1	3.9	4.0
Provisions	2.8	2.2	1.7	1.4	1.4
Tax expense	0.5	0.4	0.6	0.6	0.6
RoA (%)	1.5	1.3	1.9	1.9	2.0
Leverage ratio (x)	8.0	8.1	8.3	8.4	8.8
RoE (%)	11.9	10.8	15.5	16.0	17.7
Quarterly data					
Rs mn, Y/E Mar	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25
NII	24,434	25,254	28,663	30,050	29,483
NIM(%)	7.2	7.2	7.6	7.6	7.4
PPOP	15,834	16,553	18,385	19,409	18,551
PAT	7,212	7,327	546	10,635	9,374
EPS (Rs)	4.48	4.55	0.34	6.60	5.82


Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
27-Jul-24	193	175	Reduce	Anand Dama
20-May-24	183	175	Reduce	Anand Dama
08-Apr-24	185	175	Reduce	Anand Dama
10-Feb-24	216	270	Buy	Anand Dama
04-Dec-23	234	290	Buy	Anand Dama
30-Nov-23	226	290	Buy	Anand Dama
19-Oct-23	229	290	Buy	Anand Dama
15-Jul-23	222	285	Buy	Anand Dama
01-Jul-23	242	300	Buy	Anand Dama
20-May-23	238	300	Buy	Anand Dama
09-Mar-23	227	300	Buy	Anand Dama
21-Jan-23	237	300	Buy	Anand Dama
02-Dec-22	240	300	Buy	Anand Dama
28-Oct-22	265	330	Buy	Anand Dama
15-Sep-22	305	340	Hold	Anand Dama
23-Jul-22	286	325	Hold	Anand Dama
15-May-22	317	325	Hold	Anand Dama
23-Jan-22	296	250	Sell	Anand Dama
31-Oct-21	291	250	Sell	Anand Dama

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of October 27, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report
Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of October 27, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the October 27, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India
Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:**Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.